Who Paid My Doc
Anne Peters
Endocrinology, Diabetes & Metabolism Beverly Hills, CA Medical Doctor
NPI 1376572784 CMS profile 62644
9033 Wilshire Blvd Ste 406, Beverly Hills, CA 90211
General payments
$121,362
Research payments
$7,084
Ownership & investment interest
$0
Research they led as principal investigator
$438,793
Through program year 2025, Anne Peters of Beverly Hills, CA is reported in the CMS Open Payments database as having received $121,362 across 203 general payments and $7,084 in research payments paid to them. Separately, studies naming them as principal investigator received $438,793 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,130 | 4 | |
| 2024 | General | $4,485 | 1 | |
| 2023 | General | $3,464 | 6 | |
| 2022 | General | $8,392 | 11 | |
| 2021 | General | $15,683 | 33 | |
| 2020 | General | $41,721 | 48 | |
| 2020 | Research | $2,306 | 4 | |
| 2019 | General | $44,486 | 100 | |
| 2019 | Research | $4,779 | 13 |
Beside peers
- Anne Peters
- Endocrinology, Diabetes & Metabolism median
- Middle half of Endocrinology, Diabetes & Metabolism
- National median
In program year 2025, general payments to Anne Peters were reported at $3,130. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.
Show as a table
| Year | Anne Peters | Endocrinology, Diabetes & Metabolism median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $44,486 | $494 | $123–$2,253 | $163 |
| 2020 | $41,721 | $335 | $85–$1,841 | $114 |
| 2021 | $15,683 | $398 | $88–$1,981 | $132 |
| 2022 | $8,392 | $364 | $88–$1,568 | $149 |
| 2023 | $3,464 | $420 | $113–$1,614 | $160 |
| 2024 | $4,485 | $440 | $121–$1,646 | $164 |
| 2025 | $3,130 | $507 | $135–$1,838 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 47 drugsPart D claims
2,304
Drug cost
$1,244,038
Branded share of claims
76.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 297 | $382,948 | |
| Mounjaro Tirzepatide | Brand | 189 | $201,626 | |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | Brand | 105 | $142,007 | |
| Jardiance Empagliflozin | Brand | 101 | $102,171 | |
| Januvia Sitagliptin Phosphate | Brand | 53 | $65,259 | |
| Tresiba Flextouch U-100 Insulin Degludec | Brand | 95 | $60,529 | |
| Humalog Insulin Lispro | Brand | 110 | $34,107 | |
| Xultophy 100-3.6 Insulin Degludec/Liraglutide | Brand | 25 | $33,551 | |
| Tradjenta Linagliptin | Brand | 44 | $28,178 | |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 35 | $22,332 |
The 10 drugs with the highest cost, of 47 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 14 billing codesPaid by Medicare
$67,359
Medicare patients
236
Services billed
1,125
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Diabetes | 75% | |
| High blood pressure | 75% | |
| Ischemic heart disease | 49% | |
| Arthritis | 47% | |
| Chronic kidney disease | 35% | |
| Cancer | 20% | |
| Osteoporosis | 17% | |
| Heart failure | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
220 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Endocrinology, Diabetes & Metabolism in California
Juan Frias
Endocrinology, Diabetes & Metabolism · San Diego, CA
Joselito Cabaccan
Endocrinology, Diabetes & Metabolism · San Jose, CA
Daniel Nadeau
Endocrinology, Diabetes & Metabolism · Newport Beach, CA
Yehuda Handelsman
Endocrinology, Diabetes & Metabolism · Tarzana, CA
Helen Baron
Endocrinology, Diabetes & Metabolism · Rancho Mirage, CA
Ken Fujioka
Endocrinology, Diabetes & Metabolism · San Diego, CA
Related records
Endocrinology, Diabetes & Metabolism in California
Practitioners in the same specialty and state, ranked by reported value.
All Endocrinology, Diabetes & Metabolism
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.